Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;93(27):e183.
doi: 10.1097/MD.0000000000000183.

Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma

Affiliations

Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma

Antonio Vavallo et al. Medicine (Baltimore). 2014 Dec.

Abstract

Malignancies are one of the main causes of mortality in diabetic patients; however, to date, very limited data have been reported on the specific influence of type 2 diabetes mellitus (T2DM) on the survival of patients with renal cell carcinoma (RCC). In the present long-term retrospective study, we investigated whether T2DM may influence the overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) in patients with surgically treated RCC. Medical records of 924 patients treated by radical or partial nephrectomy for sporadic, unilateral RCC were reviewed. Patients with type-1 DM and with T2 DM receiving insulin treatment were excluded. Survival estimates were calculated according to the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate analyses were performed using the Cox regression model.Of the 924 RCC patients, 152 (16.5%) had T2DM. Mean follow-up was 68.5 months. Mean OS was 41.3 and 96.3 months in T2DM and non-T2DM patients, respectively (P < 0.0001).The estimated CSS rates at 1, 3, and 5 years in T2DM versus non-T2DM patients were 63.4% versus 76.7%, 30.4% versus 56.6%, and 16.3% versus 48.6%, respectively (P = 0.001). Mean PFS was significantly lower (31.5 vs 96.3 months; P < 0.0001) in the T2DM group. At multivariate analysis, T2DM was an independent adverse prognostic factor for OS (hazard ratio [HR] = 3.44; 95% confidence interval [CI]:2.40-4.92), CSS (HR = 6.39; 95% CI: 3.78-10.79), and PFS (HR = 4.71; 95% CI: 3.11-7.15). In conclusion, our findings suggest that patients with RCC and pre-existing T2DM have a shorter OS, increased risk of recurrence, and higher risk for kidney cancer mortality than those without diabetes.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier OS curves, stratified by T2DM and non-T2DM groups for the overall population (A). Kaplan–Meier OS curves for localized RCC (B). OS = overall survival, RCC = renal cell carcinoma, T2DM = type-2 diabetes mellitus.
FIGURE 2
FIGURE 2
Kaplan–Meier CSS curves, stratified by T2DM and non-T2DM groups for the overall population (A). Kaplan–Meier CSS curves localized RCC (B). CSS = cancer-specific survival, RCC = renal cell carcinoma, T2DM = type-2 diabetes mellitus.
FIGURE 3
FIGURE 3
Kaplan–Meier PFS curves, stratified by T2DM and non-T2DM groups for the overall population (A). Kaplan–Meier PFS curves for localized RCC (B). PFS = progression-free survival, RCC = renal cell carcinoma, T2DM = type-2 diabetes mellitus.
FIGURE 4
FIGURE 4
Kaplan–Meier CSS curves, stratified by T2DM and non-T2DM groups for radical (A) and partial nephrectomy (B). CSS = cancer-specific survival, T2DM = type-2 diabetes mellitus.
FIGURE 5
FIGURE 5
Kaplan–Meier PFS curves, stratified by T2DM and non-T2DM groups for radical (A) and partial nephrectomy (B). PFS = progression-free survival, T2DM = type-2 diabetes mellitus

Similar articles

Cited by

References

    1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.
    1. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer 2009; 16:1103–1123. - PubMed
    1. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidem 2004; 159:1160–1167. - PubMed
    1. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus. a systematic review and meta-analysis. JAMA 2008; 300:2754–2764. - PMC - PubMed
    1. Magliano DJ, Davis WA, Shaw JE, et al. Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study. Eur J Endocrinol 2012; 167:589–599. - PubMed